More on MDGL
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $535.69 |
|
|||
| Open | $534.50 | ||||
| 52 Wk High | $18.24 | ||||
| 52 Wk Low | $6.60 | ||||
| Day High | $548.53 | ||||
| Day Low | $534.50 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 72,884 | ||||
- Madrigal Pharmaceuticals (MDGL) PT Raised to $739 at Citizens Before Q2 Results
- Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
- Madrigal Pharmaceuticals receives three new resmetirom patents
- Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Ribo and Madrigal hit first milestone in siRNA MASH drug program
- Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
- Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
- Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Entities mentioned with MDGL
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Goldman Sachs | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Show More...
